STEMI resident survival guide: Difference between revisions
Line 81: | Line 81: | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{familytree | | | | | A01 | | | | | A01= '''Initial Treatment'''<br> <div style="float: left; text-align: left; width: | {{familytree | | | | | A01 | | | | | A01= '''Initial Treatment'''<br> <div style="float: left; text-align: left; width: 25em; padding:1em;"> ❑ Administer 300 mg [[aspirin]]<ref name="pmid18574276">{{cite journal| author=Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ et al.| title=Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | journal=Chest | year= 2008 | volume= 133 | issue= 6 Suppl | pages= 670S-707S | pmid=18574276 | doi=10.1378/chest.08-0691 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18574276 }} </ref> <br> | ||
❑ Administer [[oxygen]] | ❑ Administer [[oxygen]] when Sat <90%<ref name="pmid23554440">{{cite journal| author=Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S et al.| title=Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? | journal=Eur Heart J | year= 2013 | volume= 34 | issue= 22 | pages= 1630-5 | pmid=23554440 | doi=10.1093/eurheartj/eht110 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23554440 }} </ref><br> | ||
❑ Administer [[beta-blockers]] (unless contraindicated)<ref name="pmid17502569">{{cite journal| author=Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL et al.| title=Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. | journal=Circulation | year= 2007 | volume= 115 | issue= 21 | pages= 2761-88 | pmid=17502569 | doi=10.1161/CIRCULATIONAHA.107.183885 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17502569 }} </ref> <ref name="pmid15288162">{{cite journal| author=López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al.| title=Expert consensus document on beta-adrenergic receptor blockers. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 15 | pages= 1341-62 | pmid=15288162 | doi=10.1016/j.ehj.2004.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15288162 }} </ref><br></div>}} | |||
❑ Administer [[beta-blockers]] (unless contraindicated)<ref name="pmid17502569">{{cite journal| author=Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL et al.| title=Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. | journal=Circulation | year= 2007 | volume= 115 | issue= 21 | pages= 2761-88 | pmid=17502569 | doi=10.1161/CIRCULATIONAHA.107.183885 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17502569 }} </ref> <ref name="pmid15288162">{{cite journal| author=López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al.| title=Expert consensus document on beta-adrenergic receptor blockers. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 15 | pages= 1341-62 | pmid=15288162 | doi=10.1016/j.ehj.2004.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15288162 }} </ref><br> | |||
{{familytree | | | | | |!| | | | | | }} | {{familytree | | | | | |!| | | | | | }} | ||
{{familytree | | | | | B01 | | | | | | B01=<div style="float: left; text-align: center; width: | {{familytree | | | | | B01 | | | | | | B01=<div style="float: left; text-align: center; width: 25em; padding:1em;">'''Is PCI available?''' </div>}} | ||
{{familytree | | |,|-|-|^|-|-|-|.| | }} | {{familytree | | |,|-|-|^|-|-|-|.| | }} | ||
{{familytree | | C01 | | | | | C02 | | {{familytree | | C01 | | | | | C02 | | | C01=<div style="float: left; text-align: center; width: 15em; padding:1em;">'''Yes''' </div>| C02= <div style="float: left; text-align: center; width: 15em; padding:1em;">'''No''' </div> }} | ||
{{familytree | | |!| | | | | | |!| | }} | {{familytree | | |!| | | | | | |!| | }} | ||
{{familytree | | D01 | | | | | D02 | |D01=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ Send to cath lab for primary PCI</div>| D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> Evaluate for <br> ❑ The time from onset of symptoms <br> ❑ The risk of complications related to STEMI <br> ❑ The risk of bleeding with fibrinolysis <br> ❑ The presence of shock or severe HF <br> ❑ The time required for transfer to a PCI-capable hospital </div>}} | {{familytree | | D01 | | | | | D02 | | |D01=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ Send to cath lab for primary PCI</div>| D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> Evaluate for <br> ❑ The time from onset of symptoms <br> ❑ The risk of complications related to STEMI <br> ❑ The risk of bleeding with fibrinolysis <br> ❑ The presence of shock or severe HF <br> ❑ The time required for transfer to a PCI-capable hospital </div>}} | ||
{{familytree | | |!| | | | |,|-|^|-|.| }} | {{familytree | | |!| | | | |,|-|^|-|.| }} | ||
{{familytree | | E01 | | | E02 | | E03 | E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Adjunctive Antithrombotic Therapy to Support Reperfusion With Primary PCI'''</div> | E02=<div style="float: left; text-align: left; width: 15em; padding:1em;">❑ Transfer for primary PCI <br> ❑ FMC to device time as soon as possible and ≤ 120 min. </div>| E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> ❑ Administer fibrinolytic agent within 30 min of arrival </div>}} | {{familytree | | E01 | | | E02 | | E03 | E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Adjunctive Antithrombotic Therapy to Support Reperfusion With Primary PCI'''</div> | E02=<div style="float: left; text-align: left; width: 15em; padding:1em;">❑ Transfer for primary PCI <br> ❑ FMC to device time as soon as possible and ≤ 120 min. </div>| E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> ❑ Administer fibrinolytic agent within 30 min of arrival </div>}} | ||
Line 112: | Line 106: | ||
:❑ [[Tirofiban]] <br> | :❑ [[Tirofiban]] <br> | ||
::❑ Loading dose 25 mcg/kg<br> | ::❑ Loading dose 25 mcg/kg<br> | ||
::❑ Maintenance dose 0.15 mcg/kg/min</div> | F02=<div style="float: left; text-align: left; width: | ::❑ Maintenance dose 0.15 mcg/kg/min</div> | F02=<div style="float: left; text-align: left; width: 25em ; padding:1em;">'''Anticoagulant Therapy'''<br> | ||
❑ [[UFH]] <br> | ❑ [[UFH]] <br> | ||
:❑ With GP IIb/IIIa receptor antagonist planned: 50- to 70-U/kg IV bolus to achieve therapeutic ACT of 200-250 s. <br> | :❑ With GP IIb/IIIa receptor antagonist planned: 50- to 70-U/kg IV bolus to achieve therapeutic ACT of 200-250 s. <br> |
Revision as of 21:47, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Definition
ST elevation myocardial infarction (STEMI) is a syndrome defined by symptoms of myocardial ischemia (sudden chest pain and pressure, shortness of breath) associated with persistent ECG ST elevation and subsequent release of cardiac enzymes.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. STEMI is a life-threatening condition and must be treated as such irrespective of the causes.
Common Causes
- Rupture of high-risk plaque in the coronary arteries
- Occlusive Thrombus
Management
Diagnostic Approach
Shown below is an algorithm summarizing the diagnostic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction[1]
Characterize the symptoms:
❑ Diaphoresis | |||||||||||||||||||||||||||
Obtain a detailed history: ❑ Age
| |||||||||||||||||||||||||||
Examine the patient: ❑ Measure the blood pressure
| |||||||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection | |||||||||||||||||||||||||||
Order labs and tests: | |||||||||||||||||||||||||||
Order Cardiac Enzymes
| |||||||||||||||||||||||||||
❑ Symptoms + increase in Troponin + EKG ST elevation | |||||||||||||||||||||||||||
Start treatment for STEMI | |||||||||||||||||||||||||||
Therapeutic Apporach
Shown below is an algorithm depicting the therapeutic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.[1]
Initial Treatment | |||||||||||||||||||||||||
Is PCI available? | |||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||
❑ Send to cath lab for primary PCI | Evaluate for ❑ The time from onset of symptoms ❑ The risk of complications related to STEMI ❑ The risk of bleeding with fibrinolysis ❑ The presence of shock or severe HF ❑ The time required for transfer to a PCI-capable hospital | ||||||||||||||||||||||||
Adjunctive Antithrombotic Therapy to Support Reperfusion With Primary PCI | ❑ Transfer for primary PCI ❑ FMC to device time as soon as possible and ≤ 120 min. | ❑ Administer fibrinolytic agent within 30 min of arrival | |||||||||||||||||||||||
Antiplatelet Therapy ❑ P2Y12 receptor inhibitors
❑ IV GP IIb/IIIa inhibitors
| Anticoagulant Therapy ❑ UFH
| ||||||||||||||||||||||||
UFH: Unfractionated Heparin; ACT: Activated clothing time
References
- ↑ 1.0 1.1 O'Gara, Patrick T.; Kushner, Frederick G.; Ascheim, Deborah D.; Casey, Donald E.; Chung, Mina K.; de Lemos, James A.; Ettinger, Steven M.; Fang, James C.; Fesmire, Francis M.; Franklin, Barry A.; Granger, Christopher B.; Krumholz, Harlan M.; Linderbaum, Jane A.; Morrow, David A.; Newby, L. Kristin; Ornato, Joseph P.; Ou, Narith; Radford, Martha J.; Tamis-Holland, Jacqueline E.; Tommaso, Carl L.; Tracy, Cynthia M.; Woo, Y. Joseph; Zhao, David X. (2013). "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction". Journal of the American College of Cardiology. 61 (4): e78–e140. doi:10.1016/j.jacc.2012.11.019. ISSN 0735-1097.
- ↑ Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ; et al. (2008). "Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 670S–707S. doi:10.1378/chest.08-0691. PMID 18574276.
- ↑ Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S; et al. (2013). "Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?". Eur Heart J. 34 (22): 1630–5. doi:10.1093/eurheartj/eht110. PMID 23554440.
- ↑ Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL; et al. (2007). "Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention". Circulation. 115 (21): 2761–88. doi:10.1161/CIRCULATIONAHA.107.183885. PMID 17502569.
- ↑ López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H; et al. (2004). "Expert consensus document on beta-adrenergic receptor blockers". Eur Heart J. 25 (15): 1341–62. doi:10.1016/j.ehj.2004.06.002. PMID 15288162.